Nalaganje...

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://ncbi.nlm.nih.gov/pubmed/23167739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85
Oznake: Označite
Brez oznak, prvi označite!